Insulina inhalada. Características generales. Repercusión sobre la función pulmonar

EXUBERA® (Insulin human (rDNA origin)), inhalation powder, EXUBERA® inhaler, summary of product characteristics, 2006. Skyler, 2005, Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial, Diabetes Care, 28, 1630, 10.2337/diacare.28.7.1630 Quattrin, 2004, Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial, Diabetes Care, 27, 2622, 10.2337/diacare.27.11.2622 Norwood, 2007, Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera), J Clin Endocrinol Metab, 92, 2211, 10.1210/jc.2006-0631 Skyler, 2007, Two-year safety and efficacy of inhaled human insulin (exubera) in adult patients with type 1 diabetes, Diabetes Care, 30, 579, 10.2337/dc06-1863 Hollander, 2004, Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial, Diabetes Care, 27, 2356, 10.2337/diacare.27.10.2356 Weiss, 2003, Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial, Arch Intern Med, 163, 2277, 10.1001/archinte.163.19.2277 Rosenstock, 2005, Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial, Ann Intern Med, 143, 549, 10.7326/0003-4819-143-8-200510180-00005 Becker, 2006, The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin, Diabetes Care, 29, 277, 10.2337/diacare.29.02.06.dc05-1913 Himmelmann, 2003, The impact of smoking on inhaled insulin, Diabetes Care, 26, 677, 10.2337/diacare.26.3.677 Fabbri, 2006, Pulmonary safety of inhaled insulins: a review of the current data, Curr Med Res Opin, 22, 21, 10.1185/030079906X132712 Rave, 2005, Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin, Diabetes Care, 28, 1077, 10.2337/diacare.28.5.1077 Patton, 2004, Clinical pharmacokinetics and pharmacodynamics of inhaled insulin, Clin Pharmacokinet, 43, 781, 10.2165/00003088-200443120-00002 Brain, 2005, Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety, Diabetes Obes Metab, 7, S14, 10.1111/j.1463-1326.2005.00527.x Fineberg, 2005, Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (exubera) trials and a two-year extension trial, J Clin Endocrinol Metab, 90, 3287, 10.1210/jc.2004-2229 Rosenstock, 2006, Inhaled human insulin (exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (abstract) Dreyer, 2004, Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type diabetes patients poorly controlled with oral monotherapy, Diabetologia, 47, A44 Defronzo, 2005, Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial, Diabetes Care, 28, 1922, 10.2337/diacare.28.8.1922